Home > Publications database > Overestimation of grey matter atrophy in glioblastoma patients following radio(chemo)therapy. > print

001     168232
005     20240229133601.0
024 7 _ |a 10.1007/s10334-021-00922-3
|2 doi
024 7 _ |a pmid:33786695
|2 pmid
024 7 _ |a 0968-5243
|2 ISSN
024 7 _ |a 1352-8661
|2 ISSN
037 _ _ |a DKFZ-2021-00763
041 _ _ |a English
082 _ _ |a 530
100 1 _ |a Gommlich, A.
|b 0
245 _ _ |a Overestimation of grey matter atrophy in glioblastoma patients following radio(chemo)therapy.
260 _ _ |a Heidelberg
|c 2022
|b Springer
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1647269904_27307
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 35, pages 145–152 (2022)
520 _ _ |a Brain atrophy has the potential to become a biomarker for severity of radiation-induced side-effects. Particularly brain tumour patients can show great MRI signal changes over time caused by e.g. oedema, tumour progress or necrosis. The goal of this study was to investigate if such changes affect the segmentation accuracy of normal appearing brain and thus influence longitudinal volumetric measurements.T1-weighted MR images of 52 glioblastoma patients with unilateral tumours acquired before and three months after the end of radio(chemo)therapy were analysed. GM and WM volumes in the contralateral hemisphere were compared between segmenting the whole brain (full) and the contralateral hemisphere only (cl) with SPM and FSL. Relative GM and WM volumes were compared using paired t tests and correlated with the corresponding mean dose in GM and WM, respectively.Mean GM atrophy was significantly higher for full segmentation compared to cl segmentation when using SPM (mean ± std: ΔVGM,full = - 3.1% ± 3.7%, ΔVGM,cl = - 1.6% ± 2.7%; p < 0.001, d = 0.62). GM atrophy was significantly correlated with the mean GM dose with the SPM cl segmentation (r = - 0.4, p = 0.004), FSL full segmentation (r = - 0.4, p = 0.004) and FSL cl segmentation (r = -0.35, p = 0.012) but not with the SPM full segmentation (r = - 0.23, p = 0.1).For accurate normal tissue volume measurements in brain tumour patients using SPM, abnormal tissue needs to be masked prior to segmentation, however, this is not necessary when using FSL.
536 _ _ |a 315 - Bildgebung und Radioonkologie (POF4-315)
|0 G:(DE-HGF)POF4-315
|c POF4-315
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
650 _ 7 |a Atrophy
|2 Other
650 _ 7 |a Glioblastoma
|2 Other
650 _ 7 |a Proton
|2 Other
650 _ 7 |a Radiotherapy
|2 Other
650 _ 7 |a SPM
|2 Other
650 _ 7 |a Tissue segmentation
|2 Other
700 1 _ |a Raschke, F.
|b 1
700 1 _ |a Petr, J.
|b 2
700 1 _ |a Seidlitz, A.
|b 3
700 1 _ |a Jentsch, C.
|b 4
700 1 _ |a Platzek, I.
|b 5
700 1 _ |a van den Hoff, J.
|b 6
700 1 _ |a Kotzerke, J.
|b 7
700 1 _ |a Beuthien-Baumann, B.
|0 P:(DE-He78)c5312d96130619e491466891238cc117
|b 8
|u dkfz
700 1 _ |a Baumann, M.
|0 P:(DE-He78)933f7d725ac87378f459623783585a1f
|b 9
|u dkfz
700 1 _ |a Krause, M.
|0 P:(DE-He78)4be9ccb23f3e472b97743845cd2b3fe9
|b 10
|u dkfz
700 1 _ |a Troost, E. G. C.
|0 P:(DE-HGF)0
|b 11
773 _ _ |a 10.1007/s10334-021-00922-3
|0 PERI:(DE-600)1502491-X
|p 145–152
|t Magnetic resonance materials in physics, biology and medicine
|v 35
|y 2022
|x 1352-8661
909 C O |p VDB
|o oai:inrepo02.dkfz.de:168232
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 8
|6 P:(DE-He78)c5312d96130619e491466891238cc117
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 9
|6 P:(DE-He78)933f7d725ac87378f459623783585a1f
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 10
|6 P:(DE-He78)4be9ccb23f3e472b97743845cd2b3fe9
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 11
|6 P:(DE-HGF)0
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-315
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Bildgebung und Radioonkologie
|x 0
913 0 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-315
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Imaging and radiooncology
|x 0
914 1 _ |y 2021
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2021-01-30
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-01-30
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-01-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-26
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b MAGN RESON MATER PHY : 2021
|d 2022-11-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2022-11-26
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2022-11-26
920 1 _ |0 I:(DE-He78)E010-20160331
|k E010
|l E010 Radiologie
|x 0
920 1 _ |0 I:(DE-He78)E220-20160331
|k E220
|l E220 Radioonkologie/Radiobiologie
|x 1
920 1 _ |0 I:(DE-He78)DD01-20160331
|k DD01
|l DKTK DD zentral
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)E010-20160331
980 _ _ |a I:(DE-He78)E220-20160331
980 _ _ |a I:(DE-He78)DD01-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21